Gainers

• Akanda (NASDAQ:AKAN) stock moved upwards by 101.5% to $6.55 during Wednesday's regular session. The company's market cap stands at $1.7 million.
• Axe Compute (NASDAQ:AGPU) stock increased by 87.74% to $9.16. The company's market cap stands at $16.5 million.
• Inhibrx Biosciences (NASDAQ:INBX) shares moved upwards by 35.35% to $113.81. The market value of their outstanding shares is at $1.2 billion.
• Nasus Pharma (AMEX:NSRX) stock moved upwards by 23.11% to $3.94. The company's market cap stands at $37.4 million.
• cbdMD (AMEX:YCBD) shares moved upwards by 21.99% to $1.03. The company's market cap stands at $8.8 million.
• Canopy Growth (NASDAQ:CGC) shares rose 21.92% to $1.39. The company's market cap stands at $482.0 million.

Losers

• Alpha Compute (NASDAQ:ALP) stock fell 16.4% to $0.23 during Wednesday's regular session. The market value of their outstanding shares is at $6.5 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) shares fell 16.21% to $0.08.
• Psyence Biomedical (NASDAQ:PBM) shares decreased by 14.76% to $8.09. The market value of their outstanding shares is at $9.7 million.
• Community Health System (NYSE:CYH) stock declined by 13.07% to $2.69. The market value of their outstanding shares is at $429.7 million. The company's, Q1 earnings came out yesterday.
• Palisade Bio (NASDAQ:PALI) shares declined by 12.86% to $2.44. The market value of their outstanding shares is at $465.0 million.
• SILO Pharma (NASDAQ:SILO) shares fell 12.54% to $0.54. The company's market cap stands at $10.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.